Congress Park Capital’s AbbVie ABBV Stock Holding History

Congress Park Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$915K	Sell	3,637 -14	-0.4%	-$3.01K	0.25%	66
2026 Q1	$794K	Hold	3,651	–	–	0.24%	68
2025 Q4	$834K	Hold	3,651	–	–	0.25%	68
2025 Q3	$845K	Buy	3,651 +14	+0.4%	+$2.85K	0.26%	61
2025 Q2	$675K	Hold	3,637	–	–	0.22%	73
2025 Q1	$762K	Sell	3,637 -25	-0.7%	-$4.86K	0.29%	60
2024 Q4	$651K	Hold	3,662	–	–	0.24%	73
2024 Q3	$723K	Hold	3,662	–	–	0.27%	69
2024 Q2	$628K	Hold	3,662	–	–	0.25%	71
2024 Q1	$667K	Sell	3,662 -30	-0.8%	-$5.17K	0.3%	64
2023 Q4	$572K	Sell	3,692 -20	-0.5%	-$2.92K	0.28%	71
2023 Q3	$553K	Sell	3,712 -100	-3%	-$14.7K	0.29%	74
2023 Q2	$514K	Sell	3,812 -1,000	-21%	-$147K	0.26%	83
2023 Q1	$767K	Sell	4,812 -75	-2%	-$11.5K	0.4%	58
2022 Q4	$790K	Sell	4,887 -50	-1%	-$7.67K	0.46%	54
2022 Q3	$663K	Buy	4,937 +225	+5%	+$32.3K	0.38%	57
2022 Q2	$722K	Sell	4,712 -30	-0.6%	-$4.58K	0.44%	59
2022 Q1	$769K	Sell	4,742 -900	-16%	-$131K	0.39%	62
2021 Q4	$764K	Hold	5,642	–	–	0.38%	63
2021 Q3	$609K	Sell	5,642 -250	-4%	-$28.6K	0.31%	68
2021 Q2	$664K	Buy	5,892 +100	+2%	+$11.3K	0.33%	66
2021 Q1	$627K	Hold	5,792	–	–	0.35%	68
2020 Q4	$621K	Sell	5,792 -500	-8%	-$48K	0.37%	59
2020 Q3	$551K	Buy	6,292 +388	+7%	+$36.5K	0.34%	55
2020 Q2	$580K	Buy	5,904 +801	+16%	+$70.5K	0.45%	52
2020 Q1	$389K	Buy	5,103 +1	+0%	+$85	0.35%	53
2019 Q4	$452K	Buy	5,102 +2	+0%	+$166	0.33%	61
2019 Q3	$386K	Buy	5,100 +1	+0%	+$69	0.32%	60
2019 Q2	$345K	Buy	5,099 +2	+0%	+$157	0.27%	70
2019 Q1	$411K	Buy	5,097 +1	+0%	+$82	0.36%	63
2018 Q4	$470K	Buy	5,096 +1	+0%	+$88	0.52%	50
2018 Q3	$482K	Buy	5,095 +1	+0%	+$95	0.43%	58
2018 Q2	$472K	Buy	5,094 +1	+0%	+$98	0.45%	57
2018 Q1	$482K	Buy	5,093 +301	+6%	+$33.1K	0.5%	56
2017 Q4	$463K	Buy	+4,792	New	+$452K	0.47%	61

Other funds holding ABBV

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Congress Park Capital's ABBV Position: Q2 2026 in Review

Congress Park Capital reduced its AbbVie (ABBV) stake by 0.38% in Q2 2026, selling an estimated $3.01K and leaving 3,637 shares worth $915K. The position accounts for 0.25% of the portfolio, ranked #66.

Congress Park Capital first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. 2,057 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Congress Park Capital held 3,637 shares of AbbVie worth $915K as of Q2 2026.
Congress Park Capital sold 14 AbbVie shares in Q2 2026, an estimated $3.01K.
AbbVie made up 0.25% of Congress Park Capital's portfolio in Q2 2026, its #66 holding.
Congress Park Capital first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
2,057 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Congress Park Capital's 13F filing for Q2 2026, filed 14 Jul 2026.